Clinical and Genetic Profiles of 985 Chinese Families with Skeletal Dysplasia
Shanshan Li,Shanshan Lyu,Wenzhen Fu,Yunqiu Hu,Hua Yue,Lin Chen,Zhenlin Zhang
DOI: https://doi.org/10.1097/cm9.0000000000002654
IF: 6.133
2023-01-01
Chinese Medical Journal
Abstract:To the Editor:Skeletal dysplasia is a group of clinical and genetic heterogeneous disorders with primary involvement of the musculoskeletal system, including bone, cartilage, tendons, ligaments, and muscles, and is usually characterized by short stature, motion limitation, or fragility fractures, sometimes complicated with extra-skeletal phenotypes.[1] Due to the usually heterogeneous and nonspecific clinical manifestations of the disorder, identification of the pathogenic genes is crucial for patients to obtain an accurate molecular diagnosis, which not only provides explanations for patient phenotypes and ends lengthy diagnostic odysseys but also offers information concerning natural courses, specific therapies, genetic counseling for family members and prenatal diagnoses for at-risk fetuses. Genetic services have emerged in developing countries in the last decade of the twentieth century, and advances in studies concerning genetic disorders are changing the health care setting in China and the way clinicians think about the causes, diagnosis, and treatment of skeletal dysplasia.[2] However, a lack of comprehensive understanding of the clinical and genetic architecture of skeletal dysplasia in Chinese patients constrains further implementation of relevant genetic services into the health care system to a better position.[3] Additionally, there is currently no medical insurance coverage for genetic testing in China, and the tests are generally paid for by the patients themselves or through scientific research funds. These factors place new demands on clinicians for medical genetic expertise and urge the establishment of a molecular diagnostic strategy for skeletal dysplasia so that genetic testing can be applied effectively in clinical practice. The Shanghai Clinical Research Center of Bone Disease (SCRCB) is currently one of the few established centers in China focusing on the management of osteoporosis and rare skeletal disorders and is also one of the few centers that provide free genetic analysis for subjects with skeletal disorders for research purposes; thus, many suspected cases come to our center for a definite diagnosis. Here, we aim to deliver a general understanding of the clinical and genetic profiles of families diagnosed with skeletal dysplasia in our clinical center over the past 12 years, providing essential information for the effective implementation of genetic testing in health care systems in the area of skeletal dysplasia in China. Subjects with more than one of the following features and without recognizable secondary factors were enrolled for further analysis: (1) bone deformity; (2) persistent bone pain; (3) early-onset arthralgia or limited lower-limb motion indicative of premature osteoarthritis; (4) recurrent fragility fractures in women before menopause and in men ≤50 years old; (5) short stature ≤-2.0 standard deviation (SD), tall stature ≥2.0 SD, or abnormal body proportion; (6) abnormal serum calcium, phosphorus, or alkaline phosphatase levels; (7) adult women before menopause and adult men ≤50 years old with a bone mineral density Z score ≤-2.0 or patients with a bone mineral density Z score ≥2.0; and (8) bone morphological abnormalities (i.e., skull, vertebral, rib, epiphysis, metaphysis, diaphysis, pelvis) identified by radiographic examination. This study was designed in accordance with the ethics principles expressed in the Declaration of Helsinki and was approved by the Ethics Committee of Shanghai Sixth People's Hospital (Approval No. 2012-21); each subject or their legal guardian signed informed consent before participating in the study. Genomic DNA was extracted from peripheral blood leukocytes for each subject and from available lesion tissues (i.e., bone, cartilage, and skin) for subjects with suspected somatic genetic disorders. Different sequencing approaches, including Sanger sequencing, multiplex ligation-dependent probe amplification (MLPA) for large fragments of deletions or duplications, and next-generation sequencing, were applied according to the status of clinical diagnosis and disease-causing genes. Candidate variants were assessed according to the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG/AMP) standards and guidelines.[4] Data are expressed as frequencies or medians (ranges) according to the data type. The chi-square test or Fisher's exact test was used to compare categorical variables. A two-tailed value for P < 0.05 was considered statistically significant. SPSS version 13.0 for Windows (SPSS Inc., Chicago, IL, USA) was used for analysis. In the current study, we collected data from 985 subjects with skeletal dysplasia and 1446 available family members (affected relatives of all degrees). Among the 985 probands, 212 (21.5%) had a positive family history. The initial clinical diagnosis consisted of 22 disorders, and the detailed distribution and demographic data are displayed in Supplementary Table 1, https://links.lww.com/CM9/B500. A definitive molecular diagnosis was obtained in 582 (59.1%, 582/985) probands and 185 affected family members. As shown in Figure 1, the molecular diagnostic rate varied among the different clinical diagnoses. Skeletal dysplasia resulting from somatic mosaicism achieved relatively lower diagnostic yields. Of the 582 probands, Sanger sequencing identified the disease-causing gene in 516 (88.7%), MLPA identified the disease-causing gene in 11 (1.9%), targeted next-generation sequencing in 6 (1.0%), and the disease-causing gene in remaining 49 (8.4%) were identified through exome sequencing.Figure 1: Diagnostic yield of skeletal dysplasia by clinical diagnosis. The percentage indicates the molecular diagnostic yield of each clinical diagnosis (detected/total).Among the probands with a definitive molecular diagnosis, 175 (30.1%) had a positive family history. The median age at the time of their first visit was 18.0 years (range: 0.1–88.0 years); and 47.8% (278 of 582) of probands were over 18.0 years old, and 21.5% (125 of 582) were over 30.0 years old [Supplementary Figure 1A, https://links.lww.com/CM9/B500]. Predominantly, 53.1% (308 of 582) of families had an autosomal dominant inheritance pattern [Supplementary Figure 1B, https://links.lww.com/CM9/B500]. We identified 526 different disease-causing variants in the 582 families, of which 76 variants were found to be recurrent, and 25 variants occurred in more than three unrelated families [Supplementary Table 2, https://links.lww.com/CM9/B500]. Missense variants were the most frequent type of variant (47.5%, 250 of 526). We also detected a considerable proportion of copy number variants (3.4%, 18 of 526), which were identified in PHEX (n =15), SERPINF1 (n =1), SHOX (n =1), and SLCO2A1 (n =1) [Supplementary Figure 1D, https://links.lww.com/CM9/B500]. Clinical interpretation of the 526 variants based on ACMG/AMP evidence is shown in Supplementary Figures 1D and 1E, https://links.lww.com/CM9/B500. We identified 70 different disease-causing genes in the 582 families [Supplementary Table 3, https://links.lww.com/CM9/B500], and COL1A1, PHEX, SCLO2A1, COL1A2, and CLCN7 were found to be the most abundant pathogenic genes, accounting for 66.0% (384 of 582) of molecular diagnoses. Overall, 75 distinct monogenic skeletal disorders and related disorders of bone were diagnosed [Supplementary Tables 4 and 5, https://links.lww.com/CM9/B500], and 59 of those disorders were included in the 2019 revision of genetic skeletal disorders, which was further classified into 25 groups. Among them, Group 25 (osteogenesis imperfecta and decreased bone density, 37.5%, 218 of 582), Group 26 (abnormal mineralization, 19.2%, 112 of 582), and Group 24 (other sclerosing bone disorders, 14.3%, 83 of 582) were the most common categories. For the probands with a negative molecular diagnosis (n =403), the most frequent clinical diagnoses were osteogenesis imperfecta (22.2%, 89 of 403), osteochondrodysplasias (17.1%, 69 of 403), Paget's disease of bone (10.9%, 44 of 403), and hypophosphatemic rickets/ osteomalacia (9.2%, 37 of 403). The diagnostic yields of these three clinical diagnoses were significantly increased in probands with a positive family history compared with those with a negative family history (all P < 0.01) [Supplementary Table 6, https://links.lww.com/CM9/B500]. Through the systemic analysis of a Chinese cohort of 985 families affected with skeletal dysplasia, we promote a general understanding of the clinical and genetic profiles of skeletal dysplasia in China and show the relative contribution of different implicated genes to the disease burden. The relatively high proportion of subjects with a positive family history observed in the present study highlights the importance of early diagnosis for skeletal dysplasia in China, which could increase awareness of the necessity of genetic counseling and prenatal diagnosis, thereby reducing birth defects to a considerable extent. Another concern arising from the demographic data was the relatively older visiting age. Apart from the possibility of referral bias, this might be mostly due to the constitutive features of the disorders in China. Our study provided evidence that the relatively higher visiting age should not be due to the differential basis between genetic and nongenetic skeletal disorders, and more attention should be given to these adult subjects, in which some clinical or radiographic features usually become less notable after epiphyseal closure,and some specific biochemical abnormalities or limb deformities are complicated. No similar retrospective analysis of a Chinese genetic skeletal disorder cohort has been reported previously. In 2012, Cui et al[5] conducted a review of literature data published between 1978 and 2012 concerning genetic skeletal disorders in China, in which only a minority (1.16%) underwent pathogenic gene testing at that time, and a definitive molecular diagnosis was achieved in merely 1% of cases. The past decade has seen the rapid development and increasing use of various sequencing techniques in both research and clinical areas.[1,3] In this study, all subjects with skeletal dysplasia underwent disease-causing genetic tests, and we confirmed a monogenic cause in 59.1% of families. The molecular diagnostic yields varied among the different clinical diagnoses. Empirically, they largely depended on the percentage of subjects with disorders that had been well described and accurately recognized by clinicians in practice and whether the previously identified candidate pathogenic genes were known to affect the biology related to the disorder, or were located within an identified signaling pathway or within loci associated with the phenotype in large genome-wide association studies. We found COL1A1, PHEX, SCLO2A1, COL1A2, and CLCN7 to be the most abundant pathogenic genes in this study, accounting for 66.0% (384 of 582) of molecular diagnoses. These results illustrated the existence of predominant pathogenic genes in skeletal dysplasia in China and proposed the possibility of implementing a focused molecular diagnosis framework in clinical practice in conditions of limited medical resources. Meanwhile, the dominant application of Sanger sequencing in the current study underscored the strength of clinical data in molecular diagnosis. In contrast to geneticists, clinicians usually have greater access to accurate clinical data of affected families, and candidate disease-causing gene selection and detection based on clinical data would potentially be a cost-effective strategy in clinical practice. In summary, we present a comprehensive database of the largest Chinese skeletal dysplasia cohort to date, providing critical information for the effective implementation of genetic testing in health care systems in the area of skeletal dysplasia in China and potentially for the establishment of population-based disease prevention and management strategies. Further studies reanalyzing the underlying disease-causing genes in subjects with a negative molecular diagnosis, as well as continued investigation into the complexities of human bone metabolism, are needed to add to the genetic spectrum, and the contributions of structural, mitochondrial, and noncoding variants to the disease burden should also be investigated. Because it is a single-center study, the present study might have limitations in representing the exact nationwide structure of skeletal dysplasia among Chinese subjects, and we look forward to cooperating with other bone research centers in China to enroll a more comprehensive cohort of skeletal dysplasia patients that will offer more information for genetic counseling and public health policy decisions on related skeletal disorders. Acknowledgements The authors would like to acknowledge the physicians and staffs for data collection and management, and also like to appreciate all participants for their contribution to this study. Funding The study was supported by the National Key Research and Development Program of China (No. 2018YFA0800801), the National Basic Research Program of China (No. 2014CB942903), the National Natural Science Foundation of China (NSFC) (Nos. 81900807, 81770871, 81770872, 81770874), the Clinical Science and Technology Innovation Project of Shanghai Shenkang Hospital Development Center (No. SHDC12018120), Shanghai Key Clinical Center for Metabolic Disease, Shanghai Health Commission Grant (No. 2017ZZ01013), and Shanghai Municipal Key Clinical Specialty. Conflicts of interest None.